Tam Dang, MD
Ophthalmology · Richmond, VANPI 1184821803
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,552 of the $9,256 with a category attached, or 81.6%. 23 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 44.0% of the total. Reporting peaked in 2019 at $2,877 and has fallen 71.8% since, to $810 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $39.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$4K
- Alcon$1K
- AbbVie$804
- Rxsight Inc$732
- Glaukos Corporation$619
- Rayner Intraocular Lenses Limited$379
- plus $1K from 17 others
What the payments were for
- Travel & lodging$1,68518%
- Food & beverage$7,55282%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 82 | $4,075 |
| Alcon | 26 | $1,171 |
| AbbVie(2 entities) | 32 | $804 |
| Rxsight Inc | 12 | $732 |
| Glaukos Corporation | 10 | $619 |
| Rayner Intraocular Lenses Limited | 13 | $379 |
| Sun Pharmaceutical Industries Inc. | 18 | $301 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $240 |
| Ocular Therapeutix, Inc. | 11 | $210 |
| Aerie Pharmaceuticals, Inc. | 1 | $122 |
| Optovue, Inc. | 1 | $100 |
| Biotissue Holdings Inc. | 2 | $86 |
| Harrow Eye, LLC | 4 | $86 |
| Sight Sciences, Inc. | 2 | $61 |
| Carl Zeiss Meditec, Inc. | 1 | $52 |
| Tearlab Corp | 1 | $41 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| Ivantis, Inc | 1 | $33 |
| Bausch & Lomb Americas Inc. | 2 | $31 |
| Lensar, Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Novartis | 1 | $18 |
| Dutch Ophthalmic, USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Multifocal Family of 1-piece IOLS$2,013
- Tecnis Symfony IOL$1,912
- Tecnis 1-piece IOL$1,912
- Centurion$285
- KXL System$263
- Photrexa$263
- RXSIGHT CONTACT LENS$228
- RXSIGHT INJECTOR CARTRIDGE$228
- RXSIGHT INJECTOR HANDPIECE$228
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$228
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$228
- Clareon$125
- Rhopressa$122
- Rocklatan$122
- CATALYS SYSTEM$122
- AcrySof IQ PanOptix$120
- One Series Ultra$112
- One Series Ultra IOL Delivery System$112
- STELLARIS$107
- iStent Infinite$103
How this compares
$9,256 in reported general payments places this provider in the 90th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 13 | $6,818 |
| Prednisolone Acetate | 122 | $5,202 |
| Bromfenac Sodium | 18 | $5,055 |
| MoxifloxacinMoxifloxacin Hcl | 111 | $3,183 |
| Ketorolac Tromethamine | 98 | $2,974 |
| Latanoprost | 20 | $237 |
| Timolol Maleate | 24 | $237 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $804 | $6,81813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Richmond
- Ethnie JonesRichmond$2M
- Thomas JenkinsRichmond$26K
- Jessica RandolphRichmond$18K
- Nikisha RichardsRichmond$16K
- Byron LaddRichmond$7K
- Bryan SchwentRichmond$7K
- Rishi ParikhRichmond$6K
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.